Loading...
OTCM
WINT
Market cap2mUSD
Dec 05, Last price  
0.06USD
1D
10.14%
1Q
-16.71%
Jan 2017
-95.14%
Name

Windtree Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:WINT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.37%
Rev. gr., 5y
-27.38%
Revenues
0k
134,000004,600,00000582,000195,000388,0002,835,000987,0002,042,0001,485,0001,788,000198,00000000
Net income
-5m
L-72.96%
-58,904,000-46,333,000-40,005,000-39,106,000-30,240,000-19,175,000-20,965,000-37,315,000-45,215,000-44,058,000-55,170,000-39,490,000-18,446,000-20,533,000-29,862,000-30,280,000-67,636,000-39,208,000-20,291,000-5,487,000
CFO
-15m
L+14.62%
-57,668,000-39,826,000-29,395,000-31,752,000-27,415,000-24,270,000-22,698,000-32,884,000-40,454,000-41,169,000-33,504,000-33,589,000-21,045,000-15,781,000-24,663,000-25,315,000-23,664,000-19,452,000-13,437,000-15,402,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
URL
https://windtreetx.com/
IPO date
Aug 09, 1995
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT